摘要
曲妥珠单抗为乳腺癌和胃癌的治疗开辟了新方向,但其耐药问题极大地影响了疗效。目前较明确的耐药机制主要包括人表皮生长因子受体2的羧基端片段(p95HER2)过表达、磷脂酰肌醇-3-激酶(phosphatidylinositol-3-kinase,PI3K)通路部分活化、人表皮生长因子受体(human epidermal growth factor receptor,HER)信号传导上调、非HER家族生长因子受体介导信号上调。一些新型靶向药物如拉帕替尼、曲妥珠单抗共轭复合物(T-DM1)、帕妥珠单抗、依维莫司等为曲妥珠单抗耐药患者提供了新的选择。
It has been proved that the breast cancer and gastric cancer could be therapeutically targeted by trastuzumab, while the resistance of which seriously decreased the efficacy. Several mechanisms of resistance have been clarified as follows： p95HER2 overexpression, PI3K-AKT pathway constitutively activation, HER family receptor-mediated signal transduction up-regulation, and non-HER family growth factor receptor-mediated signal transduction upregulation. Some novel targeted agents, such as lapatinib, T-DM 1, pertuzumab, everolimus, offer new options for trastuzurnab-resistant patients.
出处
《解放军医学院学报》
CAS
2017年第6期571-574,共4页
Academic Journal of Chinese PLA Medical School
基金
国家十三五重点研发计划(2016YFC1303602)~~
